<?xml version="1.0" encoding="UTF-8"?>
<document id="DrugDDI.d355" origId="Carteolol"><sentence id="DrugDDI.d355.s0" origId="s0" text="Ocupress should be used with caution in patients who are receiving a beta-adrenergic blocking agent orally because of the potential for additive effects on systemic beta-blockade."><entity id="DrugDDI.d355.s0.e0" origId="s0.p0" charOffset="0-8" type="drug" text="Ocupress"/><entity id="DrugDDI.d355.s0.e1" origId="s0.p9" charOffset="69-99" type="drug" text="beta-adrenergic blocking agent"/><pair id="DrugDDI.d355.s0.p0" e1="DrugDDI.d355.s0.e0" e2="DrugDDI.d355.s0.e1" interaction="true"/></sentence><sentence id="DrugDDI.d355.s1" origId="s1" text="Close observation of the patient is recommended when a beta-blocker is administered to patients receiving catecholamine-depleting drugs such as reserpine, because of possible additive effects and the production of hypotension and/or marked bradycardia, which may produce vertigo, syncope, or postural hypotension."><entity id="DrugDDI.d355.s1.e0" origId="s1.p18" charOffset="55-67" type="drug" text="beta-blocker"/><entity id="DrugDDI.d355.s1.e1" origId="s1.p23" charOffset="130-135" type="drug" text="drugs"/><entity id="DrugDDI.d355.s1.e2" origId="s1.p24" charOffset="144-153" type="drug" text="reserpine"/><pair id="DrugDDI.d355.s1.p0" e1="DrugDDI.d355.s1.e0" e2="DrugDDI.d355.s1.e1" interaction="false"/><pair id="DrugDDI.d355.s1.p1" e1="DrugDDI.d355.s1.e0" e2="DrugDDI.d355.s1.e2" interaction="true"/><pair id="DrugDDI.d355.s1.p2" e1="DrugDDI.d355.s1.e1" e2="DrugDDI.d355.s1.e2" interaction="false"/></sentence></document>